Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

Table 1

Emetogenic potential of oral antineoplastic agents most used in solid tumors (based on MASCC and ESMO guidelines 2010).

MASCC and ESMO guidelines 2010
Degree of emetogenicity (incidence)	Agent
High (>90%)	Hexamethylmelamine
	Procarbazine
Moderate (30–90%)	Cyclophosphamide
	Temozolomide
	Vinorelbine
	Imatinib
Low (10–30%)	Capecitabine
	Etoposide
	Sunitinib
	Everolimus
	Lapatinib
Minimal (<10%)	Methotrexate
	Gefitinib
	Erlotinib
	Sorafenib